AAPL319.29-8.92 (-2.72%) ▼|ABBV257.28-2.93 (-1.13%) ▼|ABT109.88+1.09 (+1.00%) ▲|ACN188.07-5.05 (-2.62%) ▼|ADBE267.50-18.25 (-6.39%) ▼|AMAT454.82+18.91 (+4.34%) ▲|AMD469.36+13.20 (+2.89%) ▲|AMGN437.81-6.31 (-1.42%) ▼|AMT175.85-1.90 (-1.07%) ▼|AMZN255.93-2.97 (-1.15%) ▼|AVGO355.98-1.19 (-0.33%) ▼|AXP326.30-3.52 (-1.07%) ▼|BA210.42-0.09 (-0.04%) ▼|BAC62.02-0.70 (-1.12%) ▼|BKNG193.95-1.19 (-0.61%) ▼|BLK1,119.55-6.60 (-0.59%) ▼|BMY66.94-1.15 (-1.69%) ▼|BNY164.42+0.09 (+0.05%) ▲|BRK-B506.39-1.74 (-0.34%) ▼|C135.61-2.53 (-1.83%) ▼|CAT813.09+12.95 (+1.62%) ▲|CL89.84-0.26 (-0.28%) ▼|CMCSA26.46-0.20 (-0.73%) ▼|COF219.53-0.97 (-0.44%) ▼|COP134.42-1.30 (-0.96%) ▼|COST916.97-8.44 (-0.91%) ▼|CRM259.49-4.94 (-1.87%) ▼|CSCO109.14+0.53 (+0.49%) ▲|CVS96.97-0.24 (-0.24%) ▼|CVX208.62-2.70 (-1.28%) ▼|DE696.80+2.39 (+0.34%) ▲|DHR207.00-4.04 (-1.91%) ▼|DIS105.45-1.71 (-1.60%) ▼|DUK121.12-0.28 (-0.23%) ▼|EMR152.34+2.13 (+1.42%) ▲|FDX322.70-1.61 (-0.50%) ▼|GD359.51-6.36 (-1.74%) ▼|GE333.36-0.13 (-0.04%) ▼|GEV944.08+2.24 (+0.24%) ▲|GILD150.45-0.78 (-0.51%) ▼|GM87.33+0.29 (+0.33%) ▲|GOOG334.30-4.78 (-1.41%) ▼|GOOGL337.61-4.65 (-1.36%) ▼|GS1,025.29-12.64 (-1.22%) ▼|HD319.34+1.27 (+0.40%) ▲|HON208.23+0.60 (+0.29%) ▲|IBM234.15-0.57 (-0.24%) ▼|INTC95.01+3.34 (+3.64%) ▲|INTU333.77-10.53 (-3.06%) ▼|ISRG365.59-4.24 (-1.15%) ▼|JNJ276.25-2.18 (-0.78%) ▼|JPM355.45-6.62 (-1.83%) ▼|KO88.75-0.07 (-0.07%) ▼|LIN481.08-1.11 (-0.23%) ▼|LLY1,142.88-16.72 (-1.44%) ▼|LMT526.66-6.29 (-1.18%) ▼|LOW201.98+0.08 (+0.04%) ▲|LRCX302.14+9.48 (+3.24%) ▲|MA580.05-5.66 (-0.97%) ▼|MCD256.73-2.90 (-1.12%) ▼|MDLZ61.71+0.26 (+0.42%) ▲|MDT94.29+1.19 (+1.28%) ▲|META612.70+2.02 (+0.33%) ▲|MMM168.73+0.42 (+0.25%) ▲|MO69.28-0.22 (-0.31%) ▼|MRK150.76-1.58 (-1.04%) ▼|MS214.63-2.52 (-1.16%) ▼|MSFT500.52-9.60 (-1.88%) ▼|MU999.00+40.84 (+4.26%) ▲|NEE83.76-0.30 (-0.36%) ▼|NFLX79.58-3.09 (-3.74%) ▼|NKE38.31-0.47 (-1.20%) ▼|NOW140.66-4.94 (-3.39%) ▼|NVDA232.00+3.55 (+1.55%) ▲|ORCL157.58+3.54 (+2.30%) ▲|PEP138.67+0.13 (+0.09%) ▲|PFE28.56-0.25 (-0.87%) ▼|PG146.68-0.24 (-0.16%) ▼|PLTR175.86-6.67 (-3.65%) ▼|PM184.44-1.73 (-0.93%) ▼|QCOM168.90+0.33 (+0.20%) ▲|RTX200.02-2.11 (-1.04%) ▼|SBUX105.29-0.53 (-0.50%) ▼|SCHW109.12-1.26 (-1.14%) ▼|SO88.55-0.22 (-0.25%) ▼|SPG212.04+0.52 (+0.25%) ▲|T25.92-0.28 (-1.05%) ▼|TMO612.13-6.30 (-1.02%) ▼|TMUS181.93-6.09 (-3.24%) ▼|TSLA352.69-23.68 (-6.29%) ▼|TXN258.26+4.43 (+1.75%) ▲|UBER75.35-0.61 (-0.80%) ▼|UNH397.02-3.92 (-0.98%) ▼|UNP290.81+1.66 (+0.57%) ▲|UPS102.83-0.67 (-0.65%) ▼|USB63.33-0.20 (-0.31%) ▼|V374.25-4.50 (-1.19%) ▼|VZ50.24-0.36 (-0.70%) ▼|WFC89.06-0.14 (-0.15%) ▼|WMT107.63-0.79 (-0.73%) ▼|XOM160.36-1.85 (-1.14%) ▼|AAPL319.29-8.92 (-2.72%) ▼|ABBV257.28-2.93 (-1.13%) ▼|ABT109.88+1.09 (+1.00%) ▲|ACN188.07-5.05 (-2.62%) ▼|ADBE267.50-18.25 (-6.39%) ▼|AMAT454.82+18.91 (+4.34%) ▲|AMD469.36+13.20 (+2.89%) ▲|AMGN437.81-6.31 (-1.42%) ▼|AMT175.85-1.90 (-1.07%) ▼|AMZN255.93-2.97 (-1.15%) ▼|AVGO355.98-1.19 (-0.33%) ▼|AXP326.30-3.52 (-1.07%) ▼|BA210.42-0.09 (-0.04%) ▼|BAC62.02-0.70 (-1.12%) ▼|BKNG193.95-1.19 (-0.61%) ▼|BLK1,119.55-6.60 (-0.59%) ▼|BMY66.94-1.15 (-1.69%) ▼|BNY164.42+0.09 (+0.05%) ▲|BRK-B506.39-1.74 (-0.34%) ▼|C135.61-2.53 (-1.83%) ▼|CAT813.09+12.95 (+1.62%) ▲|CL89.84-0.26 (-0.28%) ▼|CMCSA26.46-0.20 (-0.73%) ▼|COF219.53-0.97 (-0.44%) ▼|COP134.42-1.30 (-0.96%) ▼|COST916.97-8.44 (-0.91%) ▼|CRM259.49-4.94 (-1.87%) ▼|CSCO109.14+0.53 (+0.49%) ▲|CVS96.97-0.24 (-0.24%) ▼|CVX208.62-2.70 (-1.28%) ▼|DE696.80+2.39 (+0.34%) ▲|DHR207.00-4.04 (-1.91%) ▼|DIS105.45-1.71 (-1.60%) ▼|DUK121.12-0.28 (-0.23%) ▼|EMR152.34+2.13 (+1.42%) ▲|FDX322.70-1.61 (-0.50%) ▼|GD359.51-6.36 (-1.74%) ▼|GE333.36-0.13 (-0.04%) ▼|GEV944.08+2.24 (+0.24%) ▲|GILD150.45-0.78 (-0.51%) ▼|GM87.33+0.29 (+0.33%) ▲|GOOG334.30-4.78 (-1.41%) ▼|GOOGL337.61-4.65 (-1.36%) ▼|GS1,025.29-12.64 (-1.22%) ▼|HD319.34+1.27 (+0.40%) ▲|HON208.23+0.60 (+0.29%) ▲|IBM234.15-0.57 (-0.24%) ▼|INTC95.01+3.34 (+3.64%) ▲|INTU333.77-10.53 (-3.06%) ▼|ISRG365.59-4.24 (-1.15%) ▼|JNJ276.25-2.18 (-0.78%) ▼|JPM355.45-6.62 (-1.83%) ▼|KO88.75-0.07 (-0.07%) ▼|LIN481.08-1.11 (-0.23%) ▼|LLY1,142.88-16.72 (-1.44%) ▼|LMT526.66-6.29 (-1.18%) ▼|LOW201.98+0.08 (+0.04%) ▲|LRCX302.14+9.48 (+3.24%) ▲|MA580.05-5.66 (-0.97%) ▼|MCD256.73-2.90 (-1.12%) ▼|MDLZ61.71+0.26 (+0.42%) ▲|MDT94.29+1.19 (+1.28%) ▲|META612.70+2.02 (+0.33%) ▲|MMM168.73+0.42 (+0.25%) ▲|MO69.28-0.22 (-0.31%) ▼|MRK150.76-1.58 (-1.04%) ▼|MS214.63-2.52 (-1.16%) ▼|MSFT500.52-9.60 (-1.88%) ▼|MU999.00+40.84 (+4.26%) ▲|NEE83.76-0.30 (-0.36%) ▼|NFLX79.58-3.09 (-3.74%) ▼|NKE38.31-0.47 (-1.20%) ▼|NOW140.66-4.94 (-3.39%) ▼|NVDA232.00+3.55 (+1.55%) ▲|ORCL157.58+3.54 (+2.30%) ▲|PEP138.67+0.13 (+0.09%) ▲|PFE28.56-0.25 (-0.87%) ▼|PG146.68-0.24 (-0.16%) ▼|PLTR175.86-6.67 (-3.65%) ▼|PM184.44-1.73 (-0.93%) ▼|QCOM168.90+0.33 (+0.20%) ▲|RTX200.02-2.11 (-1.04%) ▼|SBUX105.29-0.53 (-0.50%) ▼|SCHW109.12-1.26 (-1.14%) ▼|SO88.55-0.22 (-0.25%) ▼|SPG212.04+0.52 (+0.25%) ▲|T25.92-0.28 (-1.05%) ▼|TMO612.13-6.30 (-1.02%) ▼|TMUS181.93-6.09 (-3.24%) ▼|TSLA352.69-23.68 (-6.29%) ▼|TXN258.26+4.43 (+1.75%) ▲|UBER75.35-0.61 (-0.80%) ▼|UNH397.02-3.92 (-0.98%) ▼|UNP290.81+1.66 (+0.57%) ▲|UPS102.83-0.67 (-0.65%) ▼|USB63.33-0.20 (-0.31%) ▼|V374.25-4.50 (-1.19%) ▼|VZ50.24-0.36 (-0.70%) ▼|WFC89.06-0.14 (-0.15%) ▼|WMT107.63-0.79 (-0.73%) ▼|XOM160.36-1.85 (-1.14%) ▼|
28.3 C
New York
Friday, September 4, 2026

Tag: biologics

newssourceFORcompanyinformationcontent1releasesmarket

Outlook Therapeutics Announces LYTENAVA™ FDA Approval as the First and Only FDA-Approved Ophthalmic Bevacizumab for the Treatment of Wet AMD

Landmark FDA Approval Is an Important Milestone in Retina Care, Bringing Patients and Physicians an Ophthalmic Bevacizumab Developed Specifically for the Eye Following Years of Rigorous Clinical and Regulatory Evaluation

Harbour BioMed Announces Positive Profit Alert for 2026 Interim Results, Marking Seventh Consecutive Profitable Half-Year as Platform-Based Advantages Drive Sustainable Growth

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, July 23, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company focused on the discovery...

Castle Biosciences Announces New York State Department of Health Approval of its AdvanceAD-Tx™ Test

Approval expands access to Castle's precision medicine test designed to guide systemic treatment decision making in patients with moderate-to-severe atopic dermatitisFRIENDSWOOD, Texas, July 14,...

ADMA SHAREHOLDER ALERT: Securities Fraud Lawsuit Filed on Behalf of ADMA Biologics, Inc. Investors – Contact Kirby McInerney LLP by August 10, 2026

NEW YORK, June 26, 2026 (GLOBE NEWSWIRE) -- Kirby McInerney LLP reminds investors who purchased ADMA Biologics, Inc. (“ADMA” or the “Company”) (NASDAQ:ADMA) securities to contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below, to discuss your rights or interests in the securities fraud class action lawsuit at no cost.

Sobi receives complete response letter from FDA for NASP (nanoencapsulated sirolimus plus pegadricase)

STOCKHOLM, June 26, 2026 /PRNewswire/ --The FDA has requested additional data related to chemistry, manufacturing, and controls (CMC) and contract manufacturing facilities; no clinical...

Sobi receives complete response letter from FDA for NASP (nanoencapsulated sirolimus plus pegadricase)

STOCKHOLM, June 26, 2026 /PRNewswire/ --The FDA has requested additional data related to chemistry, manufacturing, and controls (CMC) and contract manufacturing facilities; no clinical...

$ADMA Fraud Alert: ADMA Biologics Investors Sue for Recovery in Securities Fraud Class Action after 29% Stock Drop – Investors Notified to Contact BFA...

ADMA Biologics Investors Sue for Recovery in Securities Fraud Class Action after 29% Stock Drop – Investors Notified to Contact BFA Law

Everest Medicines Announces China NMPA Acceptance of the Biologics License Application for LEROCHOL® in Adults with Hypercholesterolemia

SHANGHAI, June 26, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing...

ROSEN, THE FIRST FILING FIRM, Encourages ADMA Biologics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the...

NEW YORK, June 25, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ADMA Biologics, Inc. (NASDAQ: ADMA) between August 9, 2024 and March 25, 2026, both dates inclusive (the “Class Period”), of the important August 10, 2026 lead plaintiff deadline in the securities class action first filed by the Firm.

Chiesi Group and Arbor Biotechnologies Announce ABO-101 Granted Orphan Drug Designation by European Commission for Primary Hyperoxaluria

 ABO-101 is an investigational gene editing therapy designed to address the underlying disease biology of PH1 by reducing hepatic oxalate production

ADMA Investors Have Opportunity to Lead ADMA Biologics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

LOS ANGELES, June 25, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit...

Rare Neurological Disease Treatment Market to Reach USD 43.7 Billion by 2036 as Orphan Drug Approvals and Genetic Diagnostics Expand Specialist Care | Future...

NEWARK, Del., June 25, 2026 /PRNewswire/ -- According to a recent study by Future Market Insights (FMI), the global Rare Neurological Disease Treatment Market...

Rare Neurological Disease Treatment Market to Reach USD 43.7 Billion by 2036 as Orphan Drug Approvals and Genetic Diagnostics Expand Specialist Care | Future...

NEWARK, Del., June 25, 2026 /PRNewswire/ -- According to a recent study by Future Market Insights (FMI), the global Rare Neurological Disease Treatment Market...

Cold Chain Packaging Market Size to Reach USD 93.1 Billion by 2033, Driven by Biopharmaceutical Expansion, E-commerce Growth, and Rising Demand for Temperature-Sensitive Logistics

Global market projected to grow at a CAGR of 13.5% from 2026 to 2033 as pharmaceutical, food, and healthcare industries increasingly rely on advanced...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsBiologics

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers